Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Peak-time Sales of Radicut, Zyprexa Expected to Top \10 Bil.
June 4, 2001
- NEW PRODUCTS NEWS IN BRIEF
June 4, 2001
- Chuikyo to Review NHI Pricing Rule
June 4, 2001
- WORLD NEWS IN BRIEF
June 4, 2001
- EMA Demands Acceptance of "Moth-eaten Applications"
June 4, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 4, 2001
- Pricing Organization Accepts Eli Lilly Japan's Objection
June 4, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 4, 2001
- REGULATORY NEWS IN BRIEF
June 4, 2001
- DIAGNOSTIC NEWS IN BRIEF
June 4, 2001
- Kowa Licenses Antidiabetic Drug from Roche
June 4, 2001
- MEDICAL DEVICE NEWS IN BRIEF
June 4, 2001
- Life-cycle Management of Adalat Is Successful: Dr Ebsworth of Bayer
June 4, 2001
- Mitsubishi-Tokyo, Welfide Sign Merger Contract
June 4, 2001
- FY2000 Business Reports Show Large Gap between Poor and Excellent Performers
June 4, 2001
- BULLETIN
June 4, 2001
- EPS Goes Public, First Listed CRO in Japan
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -4-
June 4, 2001
- BUSINESS NEWS IN BRIEF
June 4, 2001
- COPRORATE ROUNDUP NEWS IN BRIEF -5-
June 4, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…